G. Michael Landis insider trades: Polaryx Therapeutics (PLYX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where G. reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | PLYX | ↑ Buy | 2,867 | $2.79 | $8K | Direct | Feb 20, 2026 (2d) |
| Sep 15, 2016 | LCI | ↓ Sell | 4,334 | $32.30 | $140K | Direct | Sep 16, 2016 (1d) |
| Aug 31, 2016 | LCI | ↓ Sell | 6,786 | $33.41 | $227K | Direct | Sep 1, 2016 (1d) |
| Feb 17, 2015 | LCI | ↓ Sell | 11,500 | $58.60 | $674K | Direct | Feb 17, 2015 (0d) |
| Feb 6, 2015 | LCI | ↓ Sell | 12,049 | $52.93 | $638K | Direct | Feb 10, 2015 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PLYX insiders
Open-market trades in the last 12 months
About G. Michael Landis's insider trades
G. Michael Landis is Chief Financial Officer at Polaryx Therapeutics (PLYX). Since Feb 6, 2015, G. has reported 1 open-market purchase worth $8K and 4 sales worth $1.7M on SEC Form 4. In the last 12 months: 1 buy ($8K).
Their filings also include shares withheld for taxes (18 filings), grants and awards (16 filings), option exercises (4 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PLYX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.